ADMA Biologics
ADMA
23 hedge funds and large institutions have $54.7M invested in ADMA Biologics in 2017 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 10 increasing their positions, 2 reducing their positions, and 5 closing their positions.
400% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 2
110% more capital invested
Capital invested by funds: $26M → $54.7M (+$28.6M)
80% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 5
49.85% more ownership
Funds ownership: 49.15% → 99% (+50%)
21% more funds holding
Funds holding: 19 → 23 (+4)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$8.67M |
| 2 |
CCM
Consonance Capital Management
New York
|
+$5.86M |
| 3 |
BC
Broadfin Capital
New York
|
+$3.08M |
| 4 |
6CM
683 Capital Management
New York
|
+$2.66M |
| 5 |
MWVC
Morgens Waterfall Vintiadis & Co
New York
|
+$1.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$263K |
| 2 |
Bank of New York Mellon
New York
|
-$66K |
| 3 |
Renaissance Technologies
New York
|
-$63K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$36K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$10K |
ADMA Hedge Fund Activity: Q4 2017 in Review
23 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in ADMA Biologics (ADMA) for Q4 2017, worth a combined $54.7M — up 110% from $26M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new ADMA positions and 5 closed out — a net gain of 4 holders — while 10 added to existing stakes and 2 trimmed.
The largest buyer was Perceptive Advisors, adding an estimated $8.67M. The largest seller was Fidelity Investments, cutting an estimated $263K.
- 23 institutional investors held ADMA Biologics (ADMA) as of Q4 2017, up from 19 in Q3 2017.
- Funds reported $54.7M of ADMA Biologics stock for Q4 2017, up 110% quarter-over-quarter.
- 9 funds opened new ADMA Biologics positions in Q4 2017 and 5 closed out, a net change of +4 holders.
- The largest ADMA Biologics buyer in Q4 2017 was Perceptive Advisors, an estimated $8.67M added.
- The largest ADMA Biologics seller in Q4 2017 was Fidelity Investments, an estimated $263K sold.
Based on aggregated 13F filings for Q4 2017.